Author

Hadiya K. Giwa

University of Massachusetts Chan Medical SchoolORCID 0009-0003-9541-8919Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Jason Robert PitarresiiD· 2 shared Katherine C. MurphyiD· 2 shared Kelly D. DeMarcoiD· 2 shared Lihua Julie ZhuiD· 2 shared Lin ZhouiD· 2 shared Marcus A. RuscettiiD· 2 shared Arthur M. MercurioiD· 1 shared Boyang MaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jason Robert PitarresiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyNature CommunicationsPeer-reviewedJun 19, 2026

Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer

Chaitanya Naimesh Parikh, Kelly D. DeMarco, Nikita Bhalerao…·Marcus A. Ruscetti

This study shows that delivering multiple cytokine and antigen mRNAs via nanoparticles can generate strong anti-tumor immunity against pancreatic cancer in mice.

2 citations

mousemultiome

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedSep 3, 2025

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer

Katherine C. Murphy, Kelly D. DeMarco, Lin Zhou…·Marcus A. Ruscetti

This study shows that MYC and p53 alterations in prostate cancer cooperate via VEGF signaling to suppress T cell activity and immunotherapy responses, and that targeting VEGFR2 can enhance immunotherapy efficacy.

10 citationstop 5%

mousehuman

𝕏 PostBluesky